logo
The cost of loneliness can be death. Here's how to find good friends

The cost of loneliness can be death. Here's how to find good friends

CTV Newsa day ago
After working from home all day, your takeout order arrives and you start binge-watching your favorite show alone. Sounds ideal, right? Except doing this routinely could shorten your life.
And that's not because of the nutritional content of your dinner. It's because having strong, positive relationships is one of the best ways to extend your life, according to research.
'Human beings just are a fundamentally social species. We have a fundamental need to belong,' said Dr. Amit Kumar, associate professor of marketing and psychology at the University of Texas at Austin's McCombs School of Business.
With everything else you have going on, why should you make a change? Because the cost of loneliness is huge.
'The mortality impact of being socially disconnected is similar to that caused by smoking up to 15 cigarettes a day, and even greater than that associated with obesity and physical inactivity,' wrote then US Surgeon General Dr. Vivek H. Murthy in his 2023 advisory on the 'healing effects' of social connection .
The lack of strong social ties has been linked to a greater risk of problems with health or well-being, including more stress, high blood pressure, premature death and poor coping skills.
But finding friends as an adult can be hard. Some people's mindsets hinder their ability to make connections, while a lack of affordable places to meet is a challenge for others, said Danielle Bayard Jackson, director of the Women's Relational Health Institute.
But the effort is worth it. Here's how Jackson and other experts suggest you combat those limitations and find your community.
Breaking down barriers to friendship
If you want to make more connections in your life, consider how you might be counteracting that goal and prepare to change, said Jackson, author of 'Fighting for Our Friendships: The Science and Art of Conflict and Connection in Women's Relationships.'
Many people have a fear of rejection, real or perceived, while others have social anxiety, Jackson said. But if you never take risks, Kumar noted, you never give your brain a chance to see that you actually can socialize.
Practicing cognitive behavioral therapy or setting yourself up for 'micro' moments to put yourself out there can help you regulate social anxiety and rejection-sensitivity, experts said.
Not everyone is going to like you, and you need to learn to regulate your emotional response to that. That could look like noting the sting and thinking, 'Well, that was awkward' — but not immediately labeling that person a jerk or deciding something about you is defective.
'Some psychologists call it exposure therapy,' Jackson said. 'I've seen them assign a client the task of going and asking for crazy things and intentionally trying to go and collect nos.'
Engage with a waiter a bit longer than normal and ask for a menu accommodation you know they will decline, Jackson said. Check out at the grocery store with a cashier instead of self-checkout to practice your social skills.
If time is an issue, think about canceling some commitments so you can prioritize your social life, experts said. But you should also change what you consider acceptable hangouts — setting time limits is OK, especially when the alternative is not seeing anyone at all.
Dr. Lauren Cook, a clinical psychologist, suggests doing mundane activities with friends more often instead of always having bigger, less frequent events focused on catching up.
If you want to see someone but also need to run errands, hit the gym or fold laundry, ask them to join you. Instead of drinks on a Friday, plan a short Tuesday game night and ask your guests to eat dinner beforehand so you only have to provide a snack.
Defy environmental challenges to socializing
Some people cite the 'collapse of third places' as a hindrance to making friends, Jackson said. That's true, she added, but those places are closing in part because of low attendance.
Today's culture of convenience is also to blame, Jackson and Cook said — think grocery delivery orders, mobile order counters, digital reading devices or livestreamed religious services. These have many perks, especially for people with mobility issues, 'but I cannot help but to think about the cost,' Jackson said.
'We tend to romanticize those serendipitous moments of, like, you're in a coffee shop and you start chatting with the girl in front of you and you guys hit it off,' Jackson said.
But that can't happen if we're acting like 'little night cooters,' Cook said — quickly hopping out, getting our food and then going back to our caves. When clients seek Jackson's help with finding friends, they list all their delivery subscriptions and other conveniences — such as frequent mobile orders — and then eliminate some, which lead to those serendipitous moments.
Don't think in black or white, Jackson said. 'If you see it as zero friends or go out and make besties, that's a lot,' she added. But if you see all that's available to you — like the neighbor or moviegoer you always run into — you can see what happens.
Finally, get off your phone. When you're always zoned in on your screen, you appear standoffish and won't notice people you might like.
Go out to meet likeminded people
To determine where to meet people, consider your values and your ideal friend, Jackson said. If you love helping people, look for volunteering opportunities. If your ideal friend reads books, where would she be on a Wednesday night? Probably at a book club meeting or a bookstore, so go to one.
Frequent local libraries, farmers markets and parks. Look online for interest clubs or events, or try an app for finding friends nearby. Take a class on something you have always wanted to do, such as learning a specific dance style or cooking a special cuisine.
Maybe even reach out to an old friend you have lost touch with, said psychologist Dr. Marisa G. Franco, an associate fellow at the University of Maryland honors program and author of 'Platonic: How the Science of Attachment Can Help You Make — and Keep — Friends.' We often underestimate how happy people will be to hear from us, she noted.
When Cook became a new mom, she brought her baby along on her walks and made many friends by asking other women about their babies and talking about her own. Cook also suggested wearing something that could be a conversation starter, such as a T-shirt featuring your favorite artist.
And don't forget you can be a leader, Cook said. 'A lot of people are hoping these opportunities will just fall in their lap. If you're not finding it, build it.'
Cook recalled when her friends hosted dinners they called 'friends of friends.' They would invite a friend who also had to bring someone. 'That completely built out their whole social world because their friends were all getting to know each other,' Cook said. 'It became this popular thing where there was a wait list.'
Another person couldn't find a quilting club for millennials, so they started a monthly class in a rented space, Cook said.
That do-it-yourself spirit is what sparked some of the platforms that matchmake strangers for restaurant dinners or provide spaces for people to start something themselves. Those initiatives include The Lonely Girls Club in the United Kingdom; California's Groundfloor, an 'after-school club' for millennials; RealRoots in the United States; and the global-based Time Left.
How to talk to strangers
Small talk may seem annoying, but it's necessary, said Cook, who also wrote 'Generation Anxiety: A Millennial and Gen Z Guide to Staying Afloat in an Uncertain World.' Deep relationships take time to build.
If you find yourself running out of topics, Cook recommends asking questions about their favorite things that are relevant to the situation — if you're at a jazz bar, for example, ask someone about their favorite jazz artists.
If your platonic interest loves hiking, say you'll send them links to a couple of good spots if they give you their number or Instagram, Jackson suggested. Later that night, send them the links. After a week, ask if they went and keep talking.
Cook also suggests using the 'listen and link' technique. As you're listening to someone, think about what you can link to the conversation, use that and build from there. If someone's talking about their trip to Costa Rica and you love monkeys, ask what kinds of monkeys they saw in Costa Rica.
One of my favorite ways to keep a conversation going with someone new? Staying curious. When someone is totally new to you, there is a whole decades-long world of information to learn about them. When you're aware of that, how could you ever have nothing to talk about? Cook agrees.
How to keep a friend
Although many people know romantic partnerships require consistent effort and nurturing, many think friendship should be the opposite: easy, natural and organic, Jackson said. This idea may be because growing up, we made friends more easily because we had classes or sports practice with them every day.
But in adulthood, that idea is a falsehood that leads to fizzled-out friendships and loneliness, Jackson said.
Maintaining friendships takes a lot of intention, experts said. Set reminders to check in, be a good listener, don't be judgmental and remember what your new acquaintances like so you can suggest meaningful ways to spend time together — and maybe even live longer.
By Kristen Rogers.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai
KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

National Post

timean hour ago

  • National Post

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

Article content New organizational structure will drive commercial growth, innovation, and overall business performance. Article content EL SEGUNDO, Calif. — KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Article content Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development, and manufacturing under a unified leadership structure for the region. Article content The formation of KARL STORZ North America reflects the company's commitment to enhancing operational efficiency, service, and value to its customers across a broader geographic footprint. Article content 'After 80 years, KARL STORZ's mission remains the same – to improve patient lives,' said Matai, President of KARL STORZ North America. 'The decision to unify our businesses across North America underscores our commitment to our customers and their evolving needs in patient care. This is an exciting opportunity to leverage exceptional talent from both countries, which will only strengthen our ability to bring solutions to market with greater speed and agility.' Article content Effective today, KARL STORZ North America encompasses six locations in the US and a Canadian and Veterinary hub in Mississauga, Ontario, a region recognized for its booming medical technology sector. Changes to the organizational structure will cause no anticipated disruption to services, product availability, or customer support. Article content About KARL STORZ Article content KARL STORZ is an innovative leader in endoscopic technology and surgical imaging solutions across virtually all surgical specialties. Its integrated OR solutions, including advancements in digital surgery, enhance collaboration to improve clinical efficiency and outcomes inside the hospital and across other sites of care. With subsidiaries around the world, KARL STORZ is a family-owned company based in Germany that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, visit Article content Article content Article content

Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment
Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment

Globe and Mail

time2 hours ago

  • Globe and Mail

Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's, ' Neurofibromatoses Pipeline Insight, 2025 ' report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Neurofibromatoses pipeline landscape. It covers the Neurofibromatoses pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibromatoses pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Neurofibromatoses Treatment Landscape. Click here to read more @ Neurofibromatoses Pipeline Outlook Key Takeaways from the Neurofibromatoses Pipeline Report In June 2025, Healx Limited announced a phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN. In June 2025, Novartis Pharmaceuticals conducted a study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib. DelveInsight's Neurofibromatoses pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Neurofibromatoses treatment. The leading Neurofibromatoses Companies such as Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Promising Neurofibromatoses Pipeline Therapies such as trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others. Discover groundbreaking developments in Neurofibromatoses Therapies! Gain in-depth knowledge of key Neurofibromatoses emerging drugs, and market opportunities @ Neurofibromatoses Clinical Trials Assessment Neurofibromatoses Emerging Drugs Profile FCN-159: Shanghai Fosun Pharmaceutical FCN-159 is a novel, proprietary and highly potent inhibitor of mitogen-activated protein kinase kinase enzymes (MEK). It is being developed by Fochon as a monotherapy and in combination to treat solid tumors. MEK is a key member in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Dysregulation of this pathway frequently occurs in many types of cancer, in particular through mutations in BRAF, KRAS and NRAS. Currently, the drug is in Phase III stage of its development for the treatment of Neurofibromatoses. HLX-1502: Healx Limited HLX-1502 is an investigational, orally administered small molecule drug developed by Healx for treating Neurofibromatosis Type 1 (NF1), a rare genetic disorder marked by tumor growth along nerves. HLX-1502 was discovered using Healx's proprietary AI platform, which accelerates the identification of potential drug candidates. The therapy has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, underscoring its potential significance for the NF1 community. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Neurofibromatosis Type 1. PAS-004: Pasithea Therapeutics Corp. PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK). Currently, the drug is in the Phase I stage of its development for the treatment of Neurofibromatosis Type 1. The Neurofibromatoses Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatoses with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatoses Treatment. Neurofibromatoses Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Neurofibromatoses Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatoses market Stay informed about the Neurofibromatoses pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Neurofibromatoses Unmet Needs Neurofibromatoses Companies Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Neurofibromatoses Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Neurofibromatoses Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Neurofibromatoses Pipeline! See the latest progress in drug development and clinical research @ Neurofibromatoses Market Drivers and Barriers, and Future Perspectives Scope of the Neurofibromatoses Pipeline Report Coverage- Global Neurofibromatoses Companies- Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others. Neurofibromatoses Pipeline Therapies- Trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others. Neurofibromatoses Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Neurofibromatoses Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Neurofibromatoses Pipeline Analysis Today! @ Neurofibromatoses Drugs and Companies Table of Contents Introduction Executive Summary Neurofibromatoses: Overview Pipeline Therapeutics Therapeutic Assessment Neurofibromatoses– DelveInsight's Analytical Perspective Late Stage Products (Phase III) FCN-159: Shanghai Fosun Pharmaceutical Drug profiles in the detailed report….. Mid Stage Products (Phase II) HLX-1502: Healx Limited Drug profiles in the detailed report….. Early Stage Products (Phase I) PAS-004: Pasithea Therapeutics Corp. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Neurofibromatoses Key Companies Neurofibromatoses Key Products Neurofibromatoses- Unmet Needs Neurofibromatoses- Market Drivers and Barriers Neurofibromatoses- Future Perspectives and Conclusion Neurofibromatoses Analyst Views Neurofibromatoses Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

IKS Health Announces Transformational Partnership with Western Washington Medical Group through Strategic Investment in Managed Service Organization
IKS Health Announces Transformational Partnership with Western Washington Medical Group through Strategic Investment in Managed Service Organization

National Post

time2 hours ago

  • National Post

IKS Health Announces Transformational Partnership with Western Washington Medical Group through Strategic Investment in Managed Service Organization

Article content DALLAS — IKS Health, a global leader in care enablement solutions supporting clinicians, staff and patients throughout the care journey, is pleased to announce a transformative expansion of its partnership with Western Washington Medical Group (WWMG), a leading independent multispecialty healthcare organization in Washington state. Article content IKS Health will make a strategic investment in a newly established management services organization (MSO) that will oversee all nonclinical operations of WWMG, including revenue cycle management, clinical documentation, HR, IT and finance. The clinical operations will continue to reside within WWMG, allowing for a clear separation of clinical and administrative functions. Article content Article content As part of this expanded partnership, IKS Health will support WWMG through the newly formed MSO, helping the medical group improve performance across both fee-for-service and value-based care models. By addressing key administrative and operational functions, IKS will position WWMG to better manage risk-based populations, reduce friction in care delivery and improve financial sustainability and patient outcomes. Article content This support will be powered by IKS Health's comprehensive, AI-enabled care enablement platform. WWMG will gain access to advanced revenue cycle management, clinical documentation through the Scribble Suite's ambient scribing solution and a patient engagement hub driven by a patent-pending AI algorithm that predicts and reduces no-shows while improving communication across the care journey. Additional services include chart reviews, document management and care coordination. Article content 'Our work with IKS Health has resulted in streamlined operations and increased efficiencies, leading us to expand our partnership and further position us for growth and, most importantly, for providing excellent patient care,' said David Russian, M.D., CEO of Western Washington Medical Group. 'This strategic partnership with IKS Health will create transformational value for WWMG with a self-sustaining model for independent medicine that benefits all stakeholders — clinicians, patients and the communities that we serve.' Article content 'Our initial investment of substantial capital into the MSO reflects our strong conviction in the long-term potential of this partnership,' said Joe Benardello, co-founder and chief growth officer at IKS Health. 'The investment will be used to grow WWMG's physician base and expand its primary care capacity. When combined with the operational efficiencies driven by the IKS Health platform, it lays the foundation for scalable and sustainable growth.' Article content 'This partnership marks a pivotal step in IKS's journey to lead the strategic transformation of healthcare,' said Sachin K. Gupta, founder and CEO of IKS Health. 'It moves us meaningfully up the value chain, well beyond commoditized point solutions, and creates a scalable and replicable path to growth. By enabling a sustainable model for physician aggregation that delivers on the quadruple aim, we're not only unlocking two powerful pools of economic value (revenue from the IKS platform and long term value from the MSO growth) — we're also deepening the moat around our Care Enablement Platform and reinforcing our long-term relevance in an increasingly dynamic healthcare landscape.' Article content About Western Washington Medical Group Article content Western Washington Medical Group (WWMG) is a team of over 100 providers in 20+ specialty areas serving patients and their families in the north Puget Sound region of Washington State. Their providers are owners of the company, and they live and work in the communities that they serve. For over 30 years, it's been WWMG's mission to provide clinicians the freedom to practice medicine with compassion, in the best interest of their patients and community. Learn more at Article content About IKS Health Article content IKS Health takes on the chores of healthcare — spanning administrative, clinical, and operational burdens — so that clinicians can focus on their core purpose: delivering great care. Combining pragmatic technology and dedicated experts, IKS Health enables stronger, financially sustainable enterprises. IKS Health's Care Enablement Platform delivers data-driven value and expertise across the care journey, and IKS Health is a partner for clinician enterprises looking to effectively scale, improve quality, and achieve cost savings through forward-thinking solutions. Founded in 2006, IKS Health's global workforce supports large health systems across the United States. For more information on IKS Health and its solutions, please visit Article content Article content Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store